Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.22.EBIT: As of FY2026 Q1, the actual value is USD -10.81 M.<h3>Financial Highlights</h3><ul><li>Total Expenses: For the quarter ended September 30, 2025, total expenses were $9.8 million, compared to $5.8 million for the same period in 2024.</li><li>Research and Development Expenses: These were $3.4 million for the quarter ended September 30, 2025, compared to $3.6 million for the same period in 2024, primarily related to the ongoing clinical development of BB-301.</li><li>General and Administrative Expenses: These increased to $6.4 million for the quarter ended September 30, 2025, from $2.2 million for the same period in 2024.</li><li>Net Loss: The net loss attributable to shareholders for the quarter ended September 30, 2025, was $9.0 million, or - $0.22 per basic and diluted share, compared to a net loss of $5.1 million, or - $0.18 per basic and diluted share for the same period in 2024.</li><li>Cash and Cash Equivalents: As of September 30, 2025, the company had $94.5 million in cash and cash equivalents.</li></ul><h3>Outlook / Guidance</h3>Benitec Biopharma Inc. plans to use the net proceeds from its recent $100 million equity financing to support the continued development and registration of its BB-301 candidate in OPMD, as well as for working capital and other general corporate purposes. The company looks forward to continued collaboration with the FDA in 2026 to advance the development of BB-301.

Benitec Biopharma | 8-K: FY2026 Q1 Revenue: USD 0